
    
      To obtain evidence of the safety of NNZ-2566 in healthy female volunteers, compared to
      placebo when administered as a 10 minute intravenous (i.v.) bolus infusion, and when
      administered as a 10-minute bolus infusion immediately followed by a continuous 72-hour
      maintenance infusion.

      To determine the blood pharmacokinetics (PK) of an intravenous dose of NNZ-2566 in healthy
      female volunteers when administered as a 10-minute bolus infusion, and when administered as a
      10-minute bolus followed by a continuous 72-hour maintenance infusion.
    
  